A complement Factor H test evaluates one of the alternative pathway’s most important protective regulators. Factor H circulates in blood, recognizes C3b, accelerates breakdown of the alternative-pathway convertase, and helps Factor I inactivate C3b before amplification damages healthy tissue. Testing is most often considered during evaluation of complement-mediated kidney disease, thrombotic microangiopathy, unexplained low C3, or a suspected rare inherited complement disorder. The central limitation is that a Factor H concentration measures how much immunoreactive protein is present—not whether it regulates complement correctly. A normal level can coexist with a disease-causing CFH variant, an autoantibody that blocks Factor H, or a defect affecting cell-surface recognition. A low level can reflect inherited deficiency, active consumption, protein loss, reduced synthesis, or treatment and specimen effects. Meaning therefore comes from the complete pattern: clinical syndrome, kidney biopsy when indicated, C3 and C4, AH50 and CH50, activation markers, autoantibody studies, genetics, medications, and timing.
- Factor H is a regulatory brake on the alternative complement pathway.
- Concentration, function, autoantibody, and genetic tests answer different questions.
- A normal Factor H level does not exclude aHUS or C3 glomerulopathy.
- Low Factor H plus persistently low C3 can suggest severe regulatory failure.
- Anti–Factor H antibodies are not detected by a routine concentration assay.
- Kidney biopsy and urgent thrombotic microangiopathy testing cannot be replaced by Factor H testing.
Table of Contents
- The protective job of Factor H
- Four different questions hidden under “Factor H testing”
- Low, high, and normal results: what each can mean
- Factor H in C3 glomerulopathy and thrombotic microangiopathy
- Autoantibodies, CFH variants, and the CFHR region
- Building meaning from the whole complement pattern
- Specimen timing and a practical follow-up pathway
The protective job of Factor H
The alternative complement pathway is always poised to amplify. A small proportion of C3 undergoes spontaneous hydrolysis, and C3b generated by any pathway can recruit Factor B. After Factor D cleaves Factor B, the C3bBb convertase produces more C3b. That feedback is valuable on a microbial surface but dangerous on the body’s own cells and in plasma.
Factor H limits that feedback in three connected ways. First, it competes with Factor B for binding to C3b, reducing formation of new convertases. Second, it accelerates decay of C3bBb by displacing Bb. Third, it acts as a cofactor for Factor I, which cleaves C3b into inactive fragments that can no longer sustain the amplification loop. The Complement Factor B test examines a component that builds the engine; Factor H testing examines a principal brake.
Factor H also distinguishes host surfaces from targets. Its amino-terminal domains regulate C3b in fluid phase, while carboxy-terminal regions recognize C3b together with host-associated molecules such as glycosaminoglycans and sialic acid. That surface-recognition role explains why some CFH variants cause serious disease despite a normal circulating concentration and seemingly preserved fluid-phase function. The protein is present, but it may not protect a kidney endothelial surface effectively.
The factor H protein family adds complexity. CFH sits in a gene region that also contains CFHR1 through CFHR5, which encode Factor H-related proteins. Those related proteins share structural domains but do not simply reproduce Factor H’s regulatory function. Copy-number changes, hybrid genes, and altered competition between Factor H and FHR proteins can influence disease. A standard Factor H concentration does not define this balance.
Failure of regulation can produce two broad clinical consequences. Near-complete inherited deficiency may cause profound C3 consumption, impaired opsonization, recurrent infection, and glomerular disease. More localized or conditional dysregulation can contribute to C3 glomerulopathy or complement-mediated thrombotic microangiopathy, often after a trigger. The result is not necessarily a globally “weak immune system”; it may be an immune system that activates in the wrong place or cannot stop efficiently.
Four different questions hidden under “Factor H testing”
A clinician ordering “Factor H” should identify the exact test because four categories are commonly involved.
Factor H concentration or antigen measures immunoreactive protein in plasma or serum, depending on the laboratory. Methods include nephelometry or enzyme-linked immunosorbent assays. The report provides units and a method-specific reference interval. This test detects quantitative deficiency or excess but cannot reliably detect qualitative dysfunction.
Factor H functional testing asks whether the patient’s protein can regulate complement. Such assays are less standardized and may be available only in specialty or research laboratories. They may assess cofactor activity, decay acceleration, C3b binding, or protection of particular surfaces. A “normal” result in one functional system may not exclude a defect expressed mainly on endothelial or renal surfaces.
Anti–Factor H autoantibody testing measures antibodies directed against Factor H. These antibodies can impair binding to C3b, interfere with regulation, or alter surface protection. The concentration of Factor H itself may be normal, low, or occasionally difficult to interpret. An antigen assay does not detect the antibody; a separate autoantibody method is required.
Genetic testing examines CFH and often a broader panel including CFI, CFB, C3, CD46, DGKE, and the CFHR region. Sequencing alone may miss copy-number changes, rearrangements, or hybrid genes unless the assay is designed to detect them. A pathogenic variant can explain mechanism and family risk, but a variant of uncertain significance does not prove causation.
Some specialty complement panels combine Factor H antigen with C3, C4, AH50 alternative-pathway activity, CH50, Factor B, CBb or Bb, and soluble C5b-9. The panel can show whether a low protein concentration occurs with consumption or pathway failure, but it still does not replace disease-specific evaluation.
The specimen also differs by method. One laboratory may validate EDTA plasma for Factor H concentration and reject serum; another may perform antigen testing in serum as part of a panel. Reference intervals therefore cannot be transferred between laboratories. The number should always be read beside its specimen type, units, assay, and printed interval.
Low, high, and normal results: what each can mean
A markedly low Factor H concentration raises concern for quantitative deficiency, but confirmation is essential. Biallelic loss-of-function CFH variants can produce severe reduction or absence. Because uncontrolled alternative-pathway activation consumes C3, affected patients may have persistently very low C3, abnormal AH50, recurrent infections with encapsulated organisms, and C3-dominant glomerular disease. Family members may have different biochemical or clinical findings depending on inheritance.
Low Factor H can also be acquired. Active complement consumption, nephrotic protein loss, protein-losing enteropathy, advanced liver dysfunction, large plasma losses, dilution, or therapeutic plasma exchange may lower circulating concentration. In nephrotic syndrome, multiple proteins are lost, so urine protein, serum albumin, immunoglobulins, and other complement components help establish context. A single low result during critical illness should not automatically be labeled hereditary deficiency.
A mildly low value is less specific. It can reflect biological variation, assay variation, heterozygous carriage, transient consumption, or the lower end of an individual baseline. Repeat testing under stable conditions and comparison with C3, activation fragments, and functional assays are usually more informative than treating the cutoff as absolute.
A normal Factor H concentration is reassuring only for gross quantity. It does not exclude a protein with impaired C3b binding, reduced cofactor activity, defective recognition of host surfaces, an anti–Factor H antibody, a CFHR rearrangement, or dysregulation elsewhere in the pathway. Most patients evaluated for complement-mediated thrombotic microangiopathy do not have a low Factor H antigen level. A normal result should therefore never be used alone to dismiss a compatible syndrome.
A high Factor H concentration is generally nonspecific. Factor H may rise with inflammation, metabolic conditions, tissue production, reduced clearance, or assay-specific factors. Research has examined Factor H and FHR ratios in kidney and other diseases, but a routine high result does not diagnose complement overactivation. Excess antigen is not equivalent to excess regulatory function, and it does not establish protection from disease.
Reference intervals also reflect the laboratory’s population and method. Age, pregnancy, acute inflammation, and kidney or liver status may shift an individual result without indicating a discrete Factor H disorder. For longitudinal follow-up, the same laboratory and assay are preferable. A change between platforms can reflect calibration or antibody-recognition differences rather than a true biological rise or fall. Minor deviations should therefore be interpreted proportionally, not as binary proof of disease.
The direction of an activation marker can differ from the direction of Factor H. For example, Factor H antigen may be normal while CBb and soluble C5b-9 are high, indicating active complement turnover despite adequate measured protein. Conversely, a low activation fragment after complement-blocking therapy may reflect drug action rather than recovery of the underlying regulatory defect.
Factor H in C3 glomerulopathy and thrombotic microangiopathy
Factor H testing is most clinically consequential when interpreted within a defined kidney syndrome. Two conditions overlap mechanistically but require different diagnostic pathways.
C3 glomerulopathy is a biopsy-defined group comprising C3 glomerulonephritis and dense deposit disease. Dominant C3 staining indicates alternative-pathway dysregulation, but the blood complement pattern can vary. Patients may present with microscopic or visible blood in urine, proteinuria, edema, hypertension, or declining kidney function. Low Complement C3 with relatively preserved C4 supports alternative-pathway consumption, yet normal C3 does not exclude C3 glomerulopathy.
After biopsy establishes C3-dominant disease, evaluation may include Factor H antigen, C3 nephritic factor, other nephritic factors, anti–Factor H antibodies, Factor B and activation fragments, soluble C5b-9, monoclonal-protein studies, and complement genetics. The purpose is to identify a driver, not to confirm what the biopsy has already shown. A Factor H result can guide mechanistic classification and family counseling, but no single blood assay explains every case.
Complement-mediated thrombotic microangiopathy often presents with microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury, hypertension, and organ dysfunction. The immediate task is not to wait for Factor H testing. Clinicians rapidly evaluate thrombotic thrombocytopenic purpura with ADAMTS13, Shiga-toxin-associated disease when relevant, severe hypertension, pregnancy-related syndromes, transplantation, drugs, autoimmune disease, infection, and other causes.
When complement-mediated TMA remains likely, Factor H antigen can be included in a second-tier complement evaluation. Low concentration may support a quantitative defect, but most pathogenic CFH variants do not necessarily lower antigen. Treatment decisions in a critically ill patient are based on the syndrome and exclusion of major alternatives, not on receipt of genetic results weeks later.
Triggers matter. Infection, pregnancy, surgery, transplantation, or severe inflammatory stress may expose an underlying regulatory vulnerability. This does not mean the trigger alone caused a hereditary disease, nor does finding a risk variant prove that every future illness is complement-mediated TMA. Clinical adjudication remains essential.
Kidney biopsy has different roles in these syndromes. It is required to classify C3 glomerulopathy. In TMA, it may demonstrate endothelial injury when the diagnosis is uncertain or kidney-limited, but biopsy is not always safe or necessary during acute thrombocytopenia. Factor H concentration cannot substitute for histopathology in either setting.
Autoantibodies, CFH variants, and the CFHR region
Anti–Factor H autoantibodies are an acquired cause of regulatory failure. They are particularly recognized in children and adolescents with complement-mediated HUS, although adults can be affected. Many antibodies target carboxy-terminal domains involved in recognizing C3b-coated host surfaces. The result can be inadequate protection of endothelial cells even when fluid-phase protein concentration appears normal.
Anti–Factor H-associated disease is strongly linked in many populations to homozygous deletion of CFHR3 and CFHR1, but the deletion itself is not sufficient to diagnose disease. It is common in some healthy populations, and not every person with the deletion develops autoantibodies. Likewise, a positive autoantibody requires interpretation with titer, assay, clinical phenotype, and treatment status.
Autoantibody concentration can change with plasma exchange, immunosuppression, B-cell-directed treatment, or recovery. Serial results may help monitor selected patients, but laboratories and units differ. A low or negative result after treatment does not show what was present before therapy. Whenever possible, a pretreatment sample should be stored without delaying urgent care.
CFH genetic disease is equally varied. Recessive variants that severely reduce protein production can cause early, persistent systemic dysregulation. Heterozygous variants affecting surface-recognition domains are more often associated with susceptibility to TMA. Other CFH variants contribute to C3 glomerulopathy or age-related macular degeneration. The same gene therefore does not imply one phenotype.
The CFH-CFHR locus is technically challenging. High sequence similarity favors recombination, deletions, duplications, and hybrid genes. A panel that reports only small sequence variants may not adequately assess structural changes. Before interpreting a “negative” genetic test, clinicians should check whether copy-number analysis and relevant CFHR rearrangements were included.
Penetrance is often incomplete. A pathogenic or likely pathogenic variant may increase risk without guaranteeing disease, and unaffected relatives may carry it. Conversely, a patient with convincing complement-mediated disease may have no identifiable variant because current testing cannot capture every regulatory mechanism. Genetic counseling helps families understand predictive testing, reproductive implications, uncertainty, and the difference between susceptibility and diagnosis.
A variant of uncertain significance should not be used alone to justify lifelong treatment or label relatives as affected. Evidence such as segregation, population frequency, protein domain, functional studies, phenotype, and expert laboratory classification determines whether a variant becomes clinically actionable.
Building meaning from the whole complement pattern
The most reliable interpretation starts with the clinical question and then aligns several layers of evidence.
| Finding | More compatible with | What it cannot establish alone |
|---|---|---|
| Very low Factor H, very low C3, abnormal AH50 | Severe quantitative regulatory deficiency or marked consumption | Whether the cause is inherited, acquired, or due to protein loss |
| Normal Factor H, low C3, high CBb/Bb | Alternative-pathway activation despite preserved antigen | Which regulator, autoantibody, or genetic mechanism is responsible |
| Normal Factor H, normal C3, acute TMA phenotype | Does not exclude surface-specific dysregulation | A diagnosis of or exclusion of complement-mediated TMA |
| Positive anti–Factor H antibody | Acquired interference with Factor H is plausible | Disease activity, causality, or optimal treatment without clinical context |
| Pathogenic CFH variant | Inherited susceptibility or deficiency, depending on variant | That a current episode is caused by complement dysregulation |
| High Factor H alone | Possible acute-phase or nonspecific increase | Overactive or adequately regulated complement |
AH50 measures the integrated alternative pathway, while CH50 measures classical-pathway initiation through the shared terminal sequence. Both may be low during broad consumption or terminal blockade. A low AH50 with a normal CH50 points toward an alternative-pathway-specific component, but a Factor H regulatory defect can produce variable patterns rather than the clean absence seen with complete structural deficiency.
C3 and C4 help show pathway preference. Persistently low C3 with normal C4 is a classic clue to alternative-pathway turnover. Low values for both can occur with classical-pathway activation, systemic immune-complex disease, severe consumption, liver disease, or mixed pathology. Complement levels can normalize between episodes, so a normal sample does not erase earlier documented abnormalities.
CBb or Bb reflects Factor B cleavage and alternative-pathway activation. Soluble C5b-9 reflects terminal-complex generation. These are activity footprints, not disease-specific biomarkers. They can rise in infection, surgery, TMA of several causes, autoimmune disease, transplantation, and other inflammatory states.
Urine and hematology results anchor the interpretation. Proteinuria, hematuria, dysmorphic red cells, casts, creatinine trajectory, platelet count, blood smear, lactate dehydrogenase, haptoglobin, and blood pressure often determine urgency more directly than Factor H antigen. Monoclonal-protein testing is particularly important in adults with C3-dominant glomerular disease because a paraprotein may drive complement dysregulation even when the clone is small.
Specimen timing and a practical follow-up pathway
Complement testing is vulnerable to preanalytic error. The performing laboratory may require EDTA plasma separated from cells within a short interval, immediate freezing, a dedicated frozen aliquot, or both serum and plasma for a panel. Repeated freeze-thaw cycles, gross hemolysis, lipemia, delayed separation, and warm transport can change results or make a specimen unacceptable.
Treatment timing is equally important. Plasma exchange removes Factor H, autoantibodies, and other complement proteins while replacement plasma adds donor Factor H. A sample collected shortly afterward may be impossible to assign to the patient’s baseline. Complement inhibitors alter functional assays and downstream activation markers. Transfusion, high-volume fluids, dialysis, immunosuppression, and severe acute inflammation can also influence the pattern.
When safe and feasible, clinicians collect pretreatment blood before plasma exchange or complement blockade, document the exact time, and freeze extra aliquots for specialty testing. This is an operational goal, not a reason to postpone emergency therapy.
A practical follow-up sequence is:
- Define the syndrome. Recurrent infection, glomerulonephritis, and TMA require different first-line evaluations.
- Verify the assay. Confirm whether the report is concentration, function, autoantibody, or genetics; note specimen type, units, and interval.
- Check broad context. Review C3, C4, AH50, CH50, kidney tests, urine findings, blood counts, liver status, albumin, medications, and recent plasma therapy.
- Repeat an unexpected concentration. Use correct handling and, when possible, a stable clinical state. A reproducible abnormality is more persuasive than one borderline value.
- Order mechanism-specific studies. Depending on phenotype, these can include anti–Factor H antibody, nephritic factors, activation fragments, functional studies, monoclonal-protein evaluation, and a genetics panel capable of structural-variant analysis.
- Involve specialists early. Nephrology, hematology, clinical immunology, complement laboratory experts, pathology, and genetics each address different parts of the problem.
Patients with suspected TMA—especially new anemia, low platelets, confusion, severe hypertension, reduced urine, chest symptoms, or acute kidney injury—need urgent medical evaluation. Patients with confirmed severe complement dysregulation or treatment-induced blockade also need individualized vaccination, infection-prevention, and emergency plans because regulating tissue injury and preserving antimicrobial defense must be balanced.
A Factor H result is most useful when it narrows a mechanistic question. A low concentration can expose a quantitative problem. A normal concentration can prevent an incorrect assumption of deficiency, but it cannot close the investigation. Autoantibodies and genetics explain different failure modes, and kidney pathology identifies the disease actually occurring in tissue. Together, these layers turn a protein measurement into clinically meaningful evidence.
References
- Complement Factor-H Concentration, Plasma. ARUP Laboratories Test Directory. Laboratory test information, 2026.
- Factor H Autoantibody, Serum. Mayo Clinic Laboratories. Laboratory test information, updated 2026.
- Atypical Hemolytic Uremic Syndrome Complement Panel, Serum and Plasma. Mayo Clinic Laboratories. Laboratory test information, updated 2026.
- C3 Glomerulopathy. StatPearls, NCBI Bookshelf. Clinical review, updated 2024.
- Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy. Hematology, American Society of Hematology Education Program. Review, 2024.
- Anti-factor H Autoantibody-Associated Hemolytic Uremic Syndrome: A Retrospective Analysis of 37 Patients. Kidney International Reports. Cohort study, 2024.
Disclaimer
This article provides general education and is not a diagnosis or treatment plan. Factor H methods, specimens, and reference intervals vary, and results require interpretation with the clinical syndrome, kidney and hematology findings, medications, and other complement studies. Suspected thrombotic microangiopathy, rapidly worsening kidney function, severe hypertension, confusion, chest symptoms, or markedly reduced urine output requires urgent medical assessment.
